TargED Biopharmaceuticals Secures $39 Million in Series A Funding for Groundbreaking MICROLYSE Drug Development

TargED Biopharmaceuticals is thrilled to announce the successful completion of a funding round, securing $39 million to expedite the development of their pioneering biopharmaceutical product, MICROLYSE. Founded in September 2018, TargED is at the forefront of addressing a critical unmet medical need—providing a targeted treatment for microvascular thrombosis, a condition that has long been underserved in the medical community. MICROLYSE uniquely utilizes enzymatic action to break down blood clots within small blood vessels, paving the way for promising advancements in the treatment of Thrombotic Thrombocytopenic Purpura (TTP), an orphan disease that triggers life-threatening episodes of microvascular thrombosis. With this latest infusion of capital, TargED is positioned to accelerate clinical trials, targeting both TTP and expanding the application of MICROLYSE to the treatment of early-stage macrovascular thrombosis, which is critical in conditions such as heart attacks and strokes. This funding is not just a milestone for TargED, but also a beacon of hope for patients suffering from these debilitating conditions. As TargED continues to innovate in the biopharmaceutical landscape, the company remains committed to its mission of delivering effective and life-saving therapies, addressing the complexities of blood clotting disorders, and ultimately improving patient outcomes. With robust support from investors, TargED is set to make significant strides in the medical field and contribute meaningfully to the global fight against thrombotic diseases.